## Rasmus Rørth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3469402/publications.pdf

Version: 2024-02-01

516710 233421 2,135 48 16 45 citations h-index g-index papers 51 51 51 3550 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	11.4	961
2	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	2.8	168
3	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	3.9	96
4	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	3.9	78
5	Association of Carpal Tunnel Syndrome With Amyloidosis, HeartÂFailure, and Adverse Cardiovascular Outcomes. Journal of the American College of Cardiology, 2019, 74, 15-23.	2.8	77
6	Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation. JAMA Cardiology, 2018, 3, 417.	6.1	73
7	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21Âyears of follow-up in the randomised Steno-2 study. Diabetologia, 2018, 61, 1724-1733.	6.3	66
8	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	4.1	63
9	The prognostic value of troponin T and Nâ€ŧerminal pro Bâ€ŧype natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	7.1	54
10	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	3.9	53
11	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	7.1	52
12	Return to the Workforce After First Hospitalization for Heart Failure. Circulation, 2016, 134, 999-1009.	1.6	50
13	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care, 2018, 41, 1285-1291.	8.6	38
14	Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction–related cardiogenic shock from 2005 to 2017: A nationwide cohort study. American Heart Journal, 2020, 229, 127-137.	2.7	24
15	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circulation: Heart Failure, 2019, 12, e005766.	3.9	21
16	Return to the workforce following coronary artery bypass grafting: A Danish nationwide cohort study. International Journal of Cardiology, 2018, 251, 15-21.	1.7	20
17	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular Diabetology, 2020, 19, 107.	6.8	18
18	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction—insights from the Betaâ€blocker Evaluation of Survival Trial. European Journal of Heart Failure, 2018, 20, 1549-1556.	7.1	17

#	Article	lF	CITATIONS
19	The economic burden of heart failure in Denmark from 1998 to 2016. European Journal of Heart Failure, 2019, 21, 1526-1531.	7.1	17
20	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. European Journal of Heart Failure, 2018, 20, 240-247.	7.1	16
21	Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e022638.	3.7	16
22	Return to the workforce following infective endocarditis—A nationwide cohort study. American Heart Journal, 2018, 195, 130-138.	2.7	15
23	MRâ€proADM as a Prognostic Marker in Patients With STâ€Segment–Elevation Myocardial Infarction—DANAMIâ€3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy. Journal of the American Heart Association, 2018, 7, .	3.7	15
24	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	7.1	14
25	Long-term Risk of Death and Hospitalization in Patients With Heart Failure and Takotsubo Syndrome: Insights From a Nationwide Cohort. Journal of Cardiac Failure, 2022, 28, 1534-1544.	1.7	14
26	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	3.0	10
27	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & Dy 1 Study. European Journal of Endocrinology, 2020, 182, 481-488.	3.7	10
28	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace, 2019, 21, 1203-1210.	1.7	9
29	The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Europace, 2019, 21, 572-580.	1.7	9
30	Nursing Home Admission and Initiation of Domiciliary Care Following Infective Endocarditis. Global Heart, 2020, 14, 41.	2.3	9
31	Severity of congenital long QT syndrome disease manifestation and risk of depression, anxiety, and mortality: a nationwide study. Europace, 2022, 24, 620-629.	1.7	7
32	Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial. Journal of Psychosomatic Research, 2020, 137, 110220.	2.6	6
33	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and endâ€stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.	7.1	6
34	Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 14-21.	3.0	4
35	Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 20-30.	3.0	4
36	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. JACC: Heart Failure, 2018, 6, 41-48.	4.1	3

#	ARTICLE	IF	CITATIONS
37	Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels—a Danish registry-based study. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 181-188.	4.0	3
38	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 2021, 16, e0255364.	2.5	3
39	The importance of $\hat{I}^2$ 2-agonists in myocardial infarction: Findings from the Eastern Danish Heart Registry. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 551-559.	1.0	2
40	Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106031.	1.6	2
41	Return to work after acute myocardial infarction with cardiogenic shock: a Danish nationwide cohort study. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 397-406.	1.0	2
42	Direct and indirect costs of heart failure in relation to diabetes status - A nationwide study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1880-1885.	2.6	2
43	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure: Author's reply. Europace, 2020, 22, 331-332.	1.7	1
44	Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e024402.	3.7	1
45	Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine. BMC Cardiovascular Disorders, 2021, 21, 622.	1.7	1
46	RETURN TO WORK FOLLOWING CORONARY ARTERY BYPASS GRAFTING: A NATIONWIDE STUDY. Journal of the American College of Cardiology, 2017, 69, 115.	2.8	0
47	VITAMIN K ANTAGONIST OR DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION: THE IMPORTANCE OF TIME IN THERAPEUTIC RANGE. Journal of the American College of Cardiology, 2017, 69, 460.	2.8	0
48	Troponin: an important prognostic biomarker in patients with heart failure and reduced ejection fraction?. European Journal of Heart Failure, 2021, 23, 1539-1540.	7.1	0